This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

2 hours ago 2

Jonathan Ponciano, The Motley Fool

Fri, March 20, 2026 astatine 11:21 AM CDT 4 min read

On February 17, 2026, Boone Capital Management disclosed a caller presumption successful Tyra Biosciences (NASDAQ:TYRA), acquiring 398,482 shares worthy $10.48 cardinal astatine quarter’s end.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Boone Capital Management reported acquiring 398,482 shares of Tyra Biosciences successful the 4th quarter. The estimated worth of these shares was $10.48 cardinal astatine quarter’s end.

This caller presumption represents 3.3% of the fund’s 13F reportable AUM arsenic of December 31, 2025.
Top holdings aft the filing:
- NYSE:MDT: $41.19 cardinal (12.9% of AUM)
- NASDAQ:MIRM: $33.27 cardinal (10.4% of AUM)
- NASDAQ:IONS: $33.05 cardinal (10.4% of AUM)
- NYSE:CI: $26.55 cardinal (8.3% of AUM)
- NASDAQ:BMRN: $24.48 cardinal (7.7% of AUM)
As of Friday, shares were priced astatine $38.67, up a staggering 253% implicit the past twelvemonth and importantly outperforming the S&P 500, which is alternatively up astir 16% successful the aforesaid period.

Metric

Value

Price (as of Friday)	$38.67
Market Capitalization	$2.1 billion
Net Income (TTM)	($119.95 million)

Tyra Biosciences develops targeted oncology therapies, with a pb campaigner (TYRA-300) focused connected FGFR3 inhibition for musculus invasive bladder cancer; further pipeline programs code FGFR2-driven cholangiocarcinoma, achondroplasia, and different FGFR/kinase-related diseases.
The steadfast operates a preclinical-stage biopharmaceutical model, generating worth done proprietary cause find and development, with aboriginal gross expected from out-licensing, milestone payments, oregon commercialization of approved therapies.
It targets oncology specialists, healthcare providers, and patients with cancers driven by FGFR/kinase mutations, arsenic good arsenic imaginable pharmaceutical partners for collaboration oregon licensing opportunities.

Tyra Biosciences is simply a biotechnology institution specializing successful the find and improvement of precision therapies for crab and uncommon diseases. The institution leverages its proprietary SNAP level to accelerate cause plan and code tumor absorption mechanisms. With a focused pipeline and expertise successful FGFR biology, Tyra aims to found a competitory presumption successful targeted oncology therapeutics.

Momentum similar this usually scares radical off, but successful biotech, a large determination tin often awesome thing much important than hype, particularly erstwhile it’s backed by existent progress.

Tyra is inactive early, but it is nary longer conscionable a concept. Management is narrowing its absorption astir a defined objective strategy, with 3 Phase 2 programs targeting indications wherever FGFR3 biology is good understood. That benignant of subject matters, particularly erstwhile superior is finite. The institution ended the twelvemonth with astir $256 cardinal successful currency and investments, capable to money operations into astatine slightest 2027, giving it capable runway done astatine slightest adjacent year.

Losses, however, are inactive significant, with nett nonaccomplishment approaching $120 cardinal for the year, but that is the outgo of advancing aggregate trials simultaneously. Compared with the fund’s larger holdings successful established healthcare and biotech names, this presumption is intelligibly much opportunistic and sized accordingly. Shares person climbed astir 47% since the extremity of past quarter, truthful it seems similar the introduction has apt paid disconnected for now.

Read Entire Article